AXGT News and Press, Axovant Gene Therapies Ltd. From 09/28/20

AXGT has promising gene therapy results in Parkinson's Disease. If future clinical results mimic the early ones, AXGT could have an addressable market of over $7.5 billion. Trading at an enterprise value of $143M, the risk reward ratio is enticing.  Nonetheless, investors sho...

Looking For Penny Stocks To Buy Before October 2020? We’re back on the hunt for penny stocks right now. The countdown has begun with the clock ticking to the end of the month and the quarter, this week. With that, it’s also good to know that penny stocks are red hot af...

Gainers: [[JAX]] +4.5%. [[AXGT]] +4.4%. [[HRI]] +3.1%. [[AVDL]] +2.3%. [[AAL]] +1.7%.Losers: [[TATT]] -6.2%. [[FNKO]] -3.5%. [[IMGN]] -3.0%. [[VIVO]] -2.6%. [[INMD]] -1.6%. For further details see: AXGT, AVDL, INMD and IMGN among after-hours movers

Did You Miss These Penny Stocks? There’s no doubt that there are plenty of penny stocks to watch this month. One of the biggest problems is choosing whether to go with the parabolic, one-day movers or search for swing trades. No matter which you choose, hopefully, you’...

Two sample breakout stocks for Week 39 with better than 10% short-term upside potential. Now up an average +206.3% YTD. Last week, SURF gained 13.3% and IMUX gained +12.1% in less than 5 trading days with the picks gaining an average +3.98% in a declining market week. The streak o...

Quick Take Taysha Gene Therapies ( TSHA ) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing genetic therapy treatments for various neurodegenerative diseases and other disorders. TSHA is still at a precl...

4 Penny Stocks To Buy Right Now According To Analysts Whether you buy penny stocks because of analysts or simply use ratings in your overall strategy, it helps to get a full lay of the land. What I mean by this is that most retail traders will look at a few facets of certain companies. They...

Axovant Gene Therapies ( AXGT +2.5% ) signs a strategic partnership with Viralgen, a leading Contract Development and Manufacturing Organization. More news on: Axovant Gene Therapies Ltd., Healthcare stocks news, Stocks on the move, Read more ...

Partnership secures access to cGMP capacity and resources at Viralgen to support the development and commercialization of Axovant’s AAV gene therapy programs for GM1 and GM2 gangliosidosis Partnership bolsters the Company’s clinical and commercial capacity and expands acc...

      -  Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30 th , 2020, with leading movement disorder specialists NEW YORK and BASEL, Switzerland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies L...